CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target

CytomX Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Mitchell Kapoor has given his Buy rating due to a combination of factors tied to CytomX’s lead colorectal cancer asset, CX-2051 (Varseta-M), and its upcoming Phase 1 expansion readout. He highlights that data expected in 1Q26 from roughly 100 patients come with attractive risk/reward, as earlier results in a smaller cohort have already shown response rates, disease control, and progression-free survival that exceed typical late-line colorectal cancer outcomes, even allowing for some deterioration as the dataset grows. Kapoor argues that if the larger study merely confirms the current signal—particularly the response durability and depth of tumor shrinkage at the 10 mg/kg dose—the market is likely to reassess the stock upward, removing the skepticism that current results reflect small-sample variability. This underpins his reiterated 12‑month price target of $10.

Kapoor also grounds his optimism in detailed feedback from key opinion leaders (KOLs), who view the interim efficacy as striking and see a realistic path to a pivotal, randomized 4th‑line trial against standard agents such as fruquintinib or regorafenib. These experts believe that response rates in the mid‑20% range or higher, coupled with progression-free survival of around five to six months and acceptable rates of severe diarrhea, would not only outperform current 4th‑line options by a wide margin but could also begin to challenge 3rd‑line standards. Kapoor emphasizes that even a scenario where the objective response rate falls to roughly half of the preliminary figure would still represent multiple‑fold improvement over existing late‑line therapies and support a clear registrational strategy. Only in a low‑efficacy downside case does he see a meaningful erosion of the long‑term thesis, leading him to conclude that the setup today offers limited downside with substantial potential upside, justifying his continued Buy stance.

According to TipRanks, Kapoor is a 4-star analyst with an average return of 4.8% and a 42.03% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Neurogene, and Crispr Therapeutics AG.